(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three most active and biggest winners today are TherapeuticsMD, Q&K International Group Limited, and Profound Medical Corp..

Rank Financial Asset Price Change Updated (EST)
1 TherapeuticsMD (TXMD) 9.95 364.95% 2022-05-31 14:51:09
2 Q&K International Group Limited (QK) 1.01 42.25% 2022-05-30 22:42:17
3 Profound Medical Corp. (PROF) 9.24 31.25% 2022-05-30 19:43:14
4 MicroStrategy (MSTR) 262.25 19.54% 2022-05-31 14:44:46
5 Syndax Pharmaceuticals (SNDX) 16.32 18.09% 2022-05-31 07:49:13
6 Rattler Midstream LP (RTLR) 17.17 17.68% 2022-05-31 03:46:13
7 Pulse Biosciences (PLSE) 2.17 17.3% 2022-05-30 19:06:06
8 PainReform Ltd. (PRFX) 0.88 17.05% 2022-05-30 19:41:14
9 Solid Biosciences (SLDB) 0.59 14.89% 2022-05-31 07:17:06
10 Sleep Number Corporation (SNBR) 48.38 14.75% 2022-05-31 07:47:14

The three most active and biggest losers today are Performance Shipping, Scienjoy Holding Corporation, and SELLAS Life Sciences Group .

Rank Financial Asset Price Change Updated (EST)
1 Performance Shipping (PSHG) 0.66 -63.56% 2022-05-30 19:55:17
2 Scienjoy Holding Corporation (SJ) 2.19 -26.26% 2022-05-31 07:15:12
3 SELLAS Life Sciences Group (SLS) 2.96 -17.78% 2022-05-31 07:43:13
4 Secoo Holding Limited (SECO) 0.23 -10.68% 2022-05-31 05:09:50
5 DraftKings (DKNG) 13.19 -10.36% 2022-05-31 14:48:49
6 Insulet (PODD) 211.84 -9.94% 2022-05-31 14:45:33
7 GameStop (GME) 124.28 -9.42% 2022-05-31 14:59:50
8 Snap (SNAP) 14.14 -9.24% 2022-05-31 14:53:16
9 Quidel (QDEL) 94.46 -8.69% 2022-05-31 14:45:43
10 Pacific Biosciences of California (PACB) 5.66 -8.35% 2022-05-31 14:30:12

Most Active Winners today

1. TherapeuticsMD (TXMD) – 364.95%

TherapeuticsMD, Inc. is a United States women’s health company. The company provides IMVEXXY, a treatment for moderate-to severe dyspareunia, and BIJUVA which is a bioidentical hormonal therapy combination of 17AY-estradiol, progesterone, for moderate to severe vasomotor symptoms. TX-015HR is a transdermal patch candidate that contains progesterone and estradiol. TX-009HR is the company’s clinical product. It contains an oral progesterone/estradiol formula. The company also produces and distributes generic and branded prescription prenatal vitamins under the vitaTrue and vitaMedMD brands. It sells prescription hormone therapy drugs and prenatal vitamins to both wholesale and retail pharmacie distributors. TherapeuticsMD, Inc., is located in Boca Raton, Florida.

NASDAQ ended the session with TherapeuticsMD rising 364.95% to $9.95 on Tuesday, after two consecutive sessions in a row of gains. NASDAQ slid 0.41% to $12,081.39, after three successive sessions in a row of gains, on what was a somewhat negative trend exchanging session today.

Volume

Today’s last reported volume for TherapeuticsMD is 7247070 which is 944.89% above its average volume of 693570.

TherapeuticsMD’s last close was $2.14, 22.18% under its 52-week high of $2.75.

TherapeuticsMD’s Sales

TherapeuticsMD’s sales growth is 33.7% for the ongoing quarter and 29.3% for the next. The company’s growth estimates for the current quarter and the next is 16.7% and 40%, respectively.

TherapeuticsMD’s Revenue

Year-on-year quarterly revenue growth grew by 114.9%, now sitting on 84.79M for the twelve trailing months.

TherapeuticsMD’s Stock Yearly Top and Bottom Value

TherapeuticsMD’s stock is valued at $9.95 at 17:32 EST, way higher than its 52-week high of $2.75.

TherapeuticsMD’s Moving Average

TherapeuticsMD’s value is way above its 50-day moving average of $0.66 and way higher than its 200-day moving average of $1.00.

More news about TherapeuticsMD.

2. Q&K International Group Limited (QK) – 42.25%

Q&K International Group Limited is a Long-Term Apartment Rental Platform in China. It leases apartments to landlords and transforms them into standard furnished rooms that it then leases out. The lease agreement also includes internet access and utilities. Q&K International Group Limited, a company based in Shanghai in the People’s Republic of China was established in 2012.

NASDAQ ended the session with Q&K International Group Limited rising 42.25% to $1.01 on Tuesday, following the last session’s upward trend. NASDAQ dropped 0.41% to $12,081.39, after three successive sessions in a row of gains, on what was a somewhat down trend trading session today.

Volume

Today’s last reported volume for Q&K International Group Limited is 66039 which is 83.21% below its average volume of 393457.

Q&K International Group Limited’s last close was $1.01, 90.38% below its 52-week high of $10.50.

Q&K International Group Limited’s Revenue

Year-on-year quarterly revenue growth declined by 27.5%, now sitting on 1.04B for the twelve trailing months.

Q&K International Group Limited’s Stock Yearly Top and Bottom Value

Q&K International Group Limited’s stock is valued at $1.01 at 17:32 EST, way under its 52-week high of $10.50 and way above its 52-week low of $0.60.

Q&K International Group Limited’s Moving Average

Q&K International Group Limited’s worth is way under its 50-day moving average of $1.13 and way below its 200-day moving average of $2.46.

More news about Q&K International Group Limited.

3. Profound Medical Corp. (PROF) – 31.25%

Profound Medical Corp. and its affiliates operate as a medical device company in commercial stage. They develop magnetic resonance-guided ablation techniques for the treatment of prostate diseases, uterine fibroids and palliative care treatment in Canada and other countries. The company’s flagship product, TULSAPRO, is used to scan magnetic resonance images in hospitals and other treatment areas. Sonalleve is a platform that can be used to treat uterine fibroids, palliative pain associated with bone metastases, and non-invasive treatments. Profound Medical Corp. has its headquarters in Mississauga (Canada).

NASDAQ ended the session with Profound Medical Corp. jumping 31.25% to $9.24 on Tuesday while NASDAQ dropped 0.41% to $12,081.39.

Volume

Today’s last reported volume for Profound Medical Corp. is 75596 which is 44.49% above its average volume of 52319.

Profound Medical Corp.’s last close was $9.24, 52.17% below its 52-week high of $19.32.

Profound Medical Corp.’s Sales

Profound Medical Corp.’s sales growth is a negative 4.8% for the current quarter and a decline by 2.3% for the next. The company’s growth estimates for the present quarter and the next is a negative 11.4% and a negative 27.6%, respectively.

Profound Medical Corp.’s Revenue

Year-on-year quarterly revenue growth declined by 65.3%, now sitting on 6.87M for the twelve trailing months.

Profound Medical Corp.’s Stock Yearly Top and Bottom Value

Profound Medical Corp.’s stock is valued at $9.24 at 17:32 EST, way under its 52-week high of $19.32 and way above its 52-week low of $6.09.

Profound Medical Corp.’s Moving Average

Profound Medical Corp.’s value is way higher than its 50-day moving average of $8.10 and way under its 200-day moving average of $11.05.

More news about Profound Medical Corp..

4. MicroStrategy (MSTR) – 19.54%

MicroStrategy Incorporated offers enterprise analytics software and other services around the world. MicroStrategy 2020 is an enterprise platform that provides analytics across multiple devices. It allows analysts and data scientists seamless access to trust-governed data within their tool. MicroStrategy support is available to customers in order to help them achieve system availability, uptime and improve their overall user experience. This includes proactive product support and highly responsive technical troubleshooting. It also offers MicroStrategy Consulting, which provides architecture and implementation services that help customers quickly achieve results and maximize returns on their investment. It provides services via channel partners and enterprise sales. The company serves companies in a variety of sectors, such as retail, technology and manufacturing. It was established in Tysons Corner in Virginia in 1989.

NASDAQ ended the session with MicroStrategy jumping 19.54% to $262.25 on Tuesday, after five sequential sessions in a row of gains. NASDAQ fell 0.41% to $12,081.39, after three sequential sessions in a row of gains, on what was a somewhat negative trend trading session today.

Volume

Today’s last reported volume for MicroStrategy is 1381680 which is 99.02% above its average volume of 694219.

MicroStrategy’s last close was $219.39, 75.39% below its 52-week high of $891.38.

The company’s growth estimates for the ongoing quarter and the next is a negative 36% and a negative 22%, respectively.

MicroStrategy’s Revenue

Year-on-year quarterly revenue growth grew by 2.4%, now sitting on 510.76M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

MicroStrategy’s stock is considered to be oversold (<=20).

MicroStrategy’s Stock Yearly Top and Bottom Value

MicroStrategy’s stock is valued at $262.25 at 17:32 EST, way under its 52-week high of $891.38 and way higher than its 52-week low of $134.09.

MicroStrategy’s Moving Average

MicroStrategy’s value is way under its 50-day moving average of $366.45 and way below its 200-day moving average of $532.84.

More news about MicroStrategy.

5. Syndax Pharmaceuticals (SNDX) – 18.09%

Syndax Pharmaceuticals, Inc., is a biopharmaceutical company in clinical stage that develops treatments for cancer. SNDX-5613, which targets Menin binding interactions with mixed-lineage leukemia 1 proteins for treatment of MLL/MLL and nucleophosmin1 mutant acute myeloidleukemia (NPM1c) is the company’s leading product candidate. SNDX-63252, or axatilimab for a monoclonal anti-colony stimulating factor 1 receptor, or CSF-1 receptor, for treatment of chronic graft-versus-host disease (cGVHD), Entinostat is being developed by the company. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.

NASDAQ ended the session with Syndax Pharmaceuticals rising 18.09% to $16.32 on Tuesday, after three consecutive sessions in a row of gains. NASDAQ fell 0.41% to $12,081.39, after three sequential sessions in a row of gains, on what was a somewhat down trend trading session today.

Volume

Today’s last reported volume for Syndax Pharmaceuticals is 483235 which is 17.15% below its average volume of 583266.

Syndax Pharmaceuticals’s last close was $16.32, 28.14% under its 52-week high of $22.71.

Syndax Pharmaceuticals’s Sales

Syndax Pharmaceuticals’s sales growth is 1083.3% for the ongoing quarter and a decline by 82.8% for the next. The company’s growth estimates for the present quarter and the next is a negative 47.7% and a negative 72.5%, respectively.

Syndax Pharmaceuticals’s Revenue

Year-on-year quarterly revenue growth grew by 33297.4%, now sitting on 139.71M for the twelve trailing months.

Syndax Pharmaceuticals’s Stock Yearly Top and Bottom Value

Syndax Pharmaceuticals’s stock is valued at $16.32 at 17:32 EST, way below its 52-week high of $22.71 and way higher than its 52-week low of $13.27.

Syndax Pharmaceuticals’s Moving Average

Syndax Pharmaceuticals’s worth is below its 50-day moving average of $16.56 and below its 200-day moving average of $17.43.

More news about Syndax Pharmaceuticals.

6. Rattler Midstream LP (RTLR) – 17.68%

Rattler Midstream LP operates, develops and owns infrastructure and midstream assets within the Permian Basin’s Midland and Delaware Basins. It provides oil-related and water-related services. It owned and operated 866 mile of crude oil, supplied water, and constructed water gathering pipelines. This acreage is located over Diamondback Energy, Inc.’s core Midland development area and Delaware Basin development area. Rattler Midstream GP LLC is the company’s general partner. The previous name of the company was Rattler Midstream Partners LP. It was founded in Midland, Texas in 2018. Diamondback Energy, Inc. is the parent company of Rattler Midstream LP.

NASDAQ ended the session with Rattler Midstream LP rising 17.68% to $17.17 on Tuesday while NASDAQ dropped 0.41% to $12,081.39.

Volume

Today’s last reported volume for Rattler Midstream LP is 526259 which is 21.87% below its average volume of 673653.

Rattler Midstream LP’s last close was $17.17, 0.23% under its 52-week high of $17.21.

Rattler Midstream LP’s Sales

Rattler Midstream LP’s sales growth is 5% for the ongoing quarter and 11.2% for the next. The company’s growth estimates for the ongoing quarter is 33.3% and a drop 73.6% for the next.

Rattler Midstream LP’s Revenue

Year-on-year quarterly revenue growth declined by 8.6%, now sitting on 396.34M for the twelve trailing months.

Rattler Midstream LP’s Stock Yearly Top and Bottom Value

Rattler Midstream LP’s stock is valued at $17.17 at 17:32 EST, under its 52-week high of $17.21 and way higher than its 52-week low of $9.51.

Rattler Midstream LP’s Moving Average

Rattler Midstream LP’s worth is way above its 50-day moving average of $14.14 and way higher than its 200-day moving average of $12.41.

More news about Rattler Midstream LP.

7. Pulse Biosciences (PLSE) – 17.3%

Pulse Biosciences, Inc. is a new bioelectric medicine business. CellFX System is a console-based, tunable platform that provides nanosecond-long pulses of electric energy to targeted non-thermally-cleared cells. It also preserves adjacent non-cellular tissues. This allows for treatment of various medical conditions by the use its Nano-Pulse Stimulation technology. In December 2015, the company, formerly Electroblate, Inc., changed its name from Pulse Biosciences, Inc. Pulse Biosciences, Inc. is an American corporation that was founded in 2014. Its headquarters are located in Hayward, California.

NASDAQ ended the session with Pulse Biosciences rising 17.3% to $2.17 on Tuesday while NASDAQ fell 0.41% to $12,081.39.

Volume

Today’s last reported volume for Pulse Biosciences is 179312 which is 27.62% below its average volume of 247768.

Pulse Biosciences’s last close was $2.17, 92.56% under its 52-week high of $29.16.

The company’s growth estimates for the ongoing quarter and the next is 26.8% and 31%, respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Pulse Biosciences’s stock is considered to be oversold (<=20).

Pulse Biosciences’s Stock Yearly Top and Bottom Value

Pulse Biosciences’s stock is valued at $2.17 at 17:32 EST, way below its 52-week high of $29.16 and way above its 52-week low of $1.41.

Pulse Biosciences’s Moving Average

Pulse Biosciences’s value is way below its 50-day moving average of $3.24 and way below its 200-day moving average of $13.31.

More news about Pulse Biosciences.

8. PainReform Ltd. (PRFX) – 17.05%

PainReform Ltd. is a specialty pharmaceutical company at the clinical stage. It develops therapeutics to provide long-lasting pain relief after surgery in Israel. PRF-110 is a clear, viscous oil-based product that can be injected directly into the wound. This provides localized and prolonged post-operative pain relief. PRF110 is being tested in Phase 3 clinical trials by the company for patients who have undergone bunionectomy or hernia surgery. PainReform Ltd., a Tel Aviv-based company was founded in 2007.

NASDAQ ended the session with PainReform Ltd. rising 17.05% to $0.88 on Tuesday while NASDAQ dropped 0.41% to $12,081.39.

Volume

Today’s last reported volume for PainReform Ltd. is 4806 which is 94.38% below its average volume of 85538.

PainReform Ltd.’s last close was $0.88, 88.8% below its 52-week high of $7.84.

PainReform Ltd.’s Stock Yearly Top and Bottom Value

PainReform Ltd.’s stock is valued at $0.88 at 17:32 EST, way below its 52-week high of $7.84 and way above its 52-week low of $0.71.

PainReform Ltd.’s Moving Average

PainReform Ltd.’s worth is way below its 50-day moving average of $1.06 and way below its 200-day moving average of $1.73.

More news about PainReform Ltd..

9. Solid Biosciences (SLDB) – 14.89%

Solid Biosciences Inc. develops therapies for Duchenne muscular Dystrophy (DMD) in the United States. SGT001 is the company’s leading product candidate. This Phase I/II trial is designed to increase functional dystrophin protein levels in patient’s muscles. SGT003 is an ext-generation gene-transfer candidate. The company also develops platform technologies such as dual gene expression which combines multiple transgenes within one vector. It is also developing novel capsids. Ultragenyx Pharmaceutical Inc. has a license agreement and collaboration with the company to create and market new gene therapies for Duchenne muscular Dystrophy. Solid Biosciences Inc. is an American company that was founded in 2013. Its headquarters are in Cambridge, Massachusetts.

NASDAQ ended the session with Solid Biosciences rising 14.89% to $0.59 on Tuesday, after three sequential sessions in a row of gains. NASDAQ dropped 0.41% to $12,081.39, after three successive sessions in a row of gains, on what was a somewhat bearish trend exchanging session today.

Volume

Today’s last reported volume for Solid Biosciences is 923745 which is 17.08% above its average volume of 788950.

Solid Biosciences’s last close was $0.59, 88% below its 52-week high of $4.92.

Solid Biosciences’s Sales

Solid Biosciences’s sales growth is 100% for the ongoing quarter and a decline by 39.2% for the next. The company’s growth estimates for the current quarter and the next is a negative 23.5% and a negative 12.5%, respectively.

Solid Biosciences’s Revenue

Year-on-year quarterly revenue growth declined by 42.3%, now sitting on 12.21M for the twelve trailing months.

Solid Biosciences’s Stock Yearly Top and Bottom Value

Solid Biosciences’s stock is valued at $0.59 at 17:32 EST, way below its 52-week high of $4.92 and way above its 52-week low of $0.42.

Solid Biosciences’s Moving Average

Solid Biosciences’s value is way under its 50-day moving average of $0.85 and way under its 200-day moving average of $1.62.

More news about Solid Biosciences.

10. Sleep Number Corporation (SNBR) – 14.75%

Sleep Number Corporation and its affiliates offer services and solutions for sleep problems in the United States. It designs, produces, sells, services, and markets bedding, including sheets and pillows. The company also offers adjustable bases with FlextFit and Smart beds from Sleep Number 360. It sells directly to customers through online and offline sales, as well as via e-commerce. It had approximately 648 stores across 50 states as of January 2, 2022. The business was previously known as Select Comfort Corporation. In November 2017, it changed its name from Sleep Number Corporation to Sleep Number Corporation. Sleep Number Corporation was established in 1987. It is located in Minneapolis, Minnesota.

NASDAQ ended the session with Sleep Number Corporation rising 14.75% to $48.38 on Tuesday while NASDAQ fell 0.41% to $12,081.39.

Volume

Today’s last reported volume for Sleep Number Corporation is 472855 which is 22.76% below its average volume of 612247.

Sleep Number Corporation’s last close was $48.38, 60.34% under its 52-week high of $121.98.

The company’s growth estimates for the current quarter is a negative 6.8% and positive 7.2% for the next.

Sleep Number Corporation’s Revenue

Year-on-year quarterly revenue growth declined by 7.2%, now sitting on 2.14B for the twelve trailing months.

Sleep Number Corporation’s Stock Yearly Top and Bottom Value

Sleep Number Corporation’s stock is valued at $48.38 at 17:32 EST, way under its 52-week high of $121.98 and way above its 52-week low of $38.86.

Sleep Number Corporation’s Moving Average

Sleep Number Corporation’s worth is above its 50-day moving average of $48.14 and way under its 200-day moving average of $73.25.

More news about Sleep Number Corporation.

Most Active Losers Today

1. Performance Shipping (PSHG) – -63.56%

Through its subsidiaries, Performance Shipping Inc. provides transportation services by way of its tanker vessel ownership. The company owned five Aframax tanker ships with combined carrying capacities of 546.094 dwt. It was founded in Athens in Greece in 2010.

NASDAQ ended the session with Performance Shipping sliding 63.56% to $0.66 on Tuesday while NASDAQ dropped 0.41% to $12,081.39.

Volume

Today’s last reported volume for Performance Shipping is 12342300 which is 4873.68% above its average volume of 248152.

Performance Shipping’s last close was $0.66, 89.25% below its 52-week high of $6.14.

Performance Shipping’s Sales

Performance Shipping’s sales growth is 41.6% for the present quarter and 46.1% for the next. The company’s growth estimates for the ongoing quarter is a negative 1.5% and positive 28.3% for the next.

Performance Shipping’s Stock Yearly Top and Bottom Value

Performance Shipping’s stock is valued at $0.66 at 17:32 EST, way below its 52-week high of $6.14 and above its 52-week low of $0.62.

Performance Shipping’s Moving Average

Performance Shipping’s value is way below its 50-day moving average of $2.67 and way under its 200-day moving average of $3.92.

More news about Performance Shipping.

2. Scienjoy Holding Corporation (SJ) – -26.26%

Scienjoy Holding Corporation offers mobile streaming services in the People’s Republic of China. It focuses on live interactive streaming, from broadcasters to viewers. The company’s platform allows users to interact and view broadcasters via online chat and virtual objects. The company reported 904,568 paid users as well as 192,389 broadcasters, as of December 31, 2020. The company operates five platforms, under the Showself Live Streaming and Lehai Live Streaming names. It also provides technical support and advice services. Scienjoy Holding Corporation, which was established in 2011, is located in Beijing (the People’s Republic of China). Scienjoy Holding Corporation, a subsidiary Lavacano Holdings Limited.

NASDAQ ended the session with Scienjoy Holding Corporation dropping 26.26% to $2.19 on Tuesday, after two sequential sessions in a row of gains. NASDAQ slid 0.41% to $12,081.39, after three successive sessions in a row of gains, on what was a somewhat negative trend exchanging session today.

Volume

Today’s last reported volume for Scienjoy Holding Corporation is 635944 which is 4.89% below its average volume of 668660.

Scienjoy Holding Corporation’s last close was $2.19, 75.48% under its 52-week high of $8.93.

Scienjoy Holding Corporation’s Revenue

Year-on-year quarterly revenue growth grew by 30.5%, now sitting on 1.63B for the twelve trailing months.

Scienjoy Holding Corporation’s Stock Yearly Top and Bottom Value

Scienjoy Holding Corporation’s stock is valued at $2.19 at 17:32 EST, way below its 52-week high of $8.93 and way above its 52-week low of $1.75.

Scienjoy Holding Corporation’s Moving Average

Scienjoy Holding Corporation’s worth is way below its 50-day moving average of $3.54 and way under its 200-day moving average of $4.70.

More news about Scienjoy Holding Corporation.

3. SELLAS Life Sciences Group (SLS) – -17.78%

SELLAS Life Sciences Group, Inc. is a biopharmaceutical company in late stage. It focuses on developing novel immunotherapies against cancer for various indications within the United States. Galinpepimut S (GPS), the company’s leading product candidate, is a cancer immunotherapeutic drug that targets Wilms Tumor 1. It is currently in Phase III clinical trials to treat acute myeloidleukemia. Phase 1/2 clinical trials are underway for the treatment of ovarian cancer. Nelipepimut S, a new cancer immunotherapy targeting human epidermal Growth Factor receptor 2, is also being developed by the company. It’s currently in Phase 2b clinical trial for treatment of early-stage breast carcinoma. Merck & Co., Inc. has partnered with it to test GPS in conjunction with PD1 inhibitor pembrolizumab. The Phase 1/2 trial enrolls patients with up to 5 cancer indications, including solid tumors and hematologic malignancies. New York is the headquarters of this company, which was established in 2012.

NASDAQ ended the session with SELLAS Life Sciences Group sliding 17.78% to $2.96 on Tuesday, following the last session’s upward trend. NASDAQ dropped 0.41% to $12,081.39, after three sequential sessions in a row of gains, on what was a somewhat negative trend exchanging session today.

Volume

Today’s last reported volume for SELLAS Life Sciences Group is 111191 which is 61.36% below its average volume of 287769.

SELLAS Life Sciences Group ‘s last close was $2.96, 80.37% under its 52-week high of $15.08.

The company’s growth estimates for the ongoing quarter and the next is a negative 137.5% and a negative 63.3%, respectively.

SELLAS Life Sciences Group ‘s Revenue

Year-on-year quarterly revenue growth declined by 100%, now sitting on 7.6M for the twelve trailing months.

SELLAS Life Sciences Group ‘s Stock Yearly Top and Bottom Value

SELLAS Life Sciences Group ‘s stock is valued at $2.96 at 17:32 EST, way below its 52-week high of $15.08 and way higher than its 52-week low of $2.10.

SELLAS Life Sciences Group ‘s Moving Average

SELLAS Life Sciences Group ‘s worth is way under its 50-day moving average of $3.90 and way under its 200-day moving average of $6.48.

More news about SELLAS Life Sciences Group .

4. Secoo Holding Limited (SECO) – -10.68%

Through its subsidiaries, Secoo Holding Limited operates an online and offline integrated shopping portal in China, Hong Kong and around the world. The company offers upscale brands products and services including handbags. It also sells clothing, shoes, accessories, jewellery, cosmetics and skin care products. It also provides a platform for third-party merchants that allows them to sell upscale products or services. Parkson Group has formed a strategic alliance between Secoo Holding Limited and Secoo Holding Limited. It was founded in 2011, and its headquarters are in Beijing, China.

NASDAQ ended the session with Secoo Holding Limited dropping 10.68% to $0.23 on Tuesday while NASDAQ slid 0.41% to $12,081.39.

Volume

Today’s last reported volume for Secoo Holding Limited is 35191 which is 89.79% below its average volume of 344993.

Secoo Holding Limited’s last close was $0.23, 91.09% below its 52-week high of $2.58.

Secoo Holding Limited’s Sales

Secoo Holding Limited’s sales growth is 37.3% for the present quarter and 17.5% for the next.

Secoo Holding Limited’s Revenue

Year-on-year quarterly revenue growth declined by 41.6%, now sitting on 5.23B for the twelve trailing months.

Secoo Holding Limited’s Stock Yearly Top and Bottom Value

Secoo Holding Limited’s stock is valued at $0.23 at 17:32 EST, way below its 52-week high of $2.58 and above its 52-week low of $0.22.

Secoo Holding Limited’s Moving Average

Secoo Holding Limited’s worth is way under its 50-day moving average of $0.33 and way below its 200-day moving average of $0.73.

More news about Secoo Holding Limited.

5. DraftKings (DKNG) – -10.36%

DraftKings Inc. is a US-based digital gaming and entertainment company. It offers daily sports and betting opportunities as well as iGaming. The company is involved in designing and developing software that allows for sports betting, casino gaming platforms and products to be sold online or at retail. It distributes its products through a variety of channels including websites, app downloads and digital direct-to-consumer platforms. DraftKings Inc. has its headquarters in Boston, Massachusetts.

NASDAQ ended the session with DraftKings dropping 10.36% to $13.19 on Tuesday while NASDAQ dropped 0.41% to $12,081.39.

Volume

Today’s last reported volume for DraftKings is 28669500 which is 18.65% above its average volume of 24162100.

DraftKings’s last close was $14.72, 77.21% under its 52-week high of $64.58.

DraftKings’s Sales

DraftKings’s sales growth is 42.9% for the current quarter and 91.3% for the next. The company’s growth estimates for the present quarter is a negative 5.3% and positive 14.1% for the next.

DraftKings’s Revenue

Year-on-year quarterly revenue growth grew by 46.9%, now sitting on 1.3B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

DraftKings’s stock is considered to be oversold (<=20).

DraftKings’s Stock Yearly Top and Bottom Value

DraftKings’s stock is valued at $13.19 at 17:33 EST, way below its 52-week high of $64.58 and way higher than its 52-week low of $9.77.

DraftKings’s Moving Average

DraftKings’s worth is way under its 50-day moving average of $15.71 and way below its 200-day moving average of $31.67.

More news about DraftKings.

6. Insulet (PODD) – -9.94%

Insulet Corporation designs, produces, and markets insulin delivery systems to people suffering from insulin-dependent diabetes. The Omnipod System consists of two devices. One is a disposable, self-adhesive Omnipod device, which can be worn on the body up to 3 days. It also includes a wireless companion called the personal diabetes manager, which can be carried around with you for as long as three days. It sells products through independent distributors, pharmacy channels and directly within the United States, Canada and Europe. Insulet Corporation was established in Acton in Massachusetts in 2000.

NASDAQ ended the session with Insulet sliding 9.94% to $211.84 on Tuesday while NASDAQ dropped 0.41% to $12,081.39.

Volume

Today’s last reported volume for Insulet is 1379740 which is 129.4% above its average volume of 601430.

Insulet’s last close was $235.21, 27.59% under its 52-week high of $324.81.

The company’s growth estimates for the ongoing quarter and the next is 162.2% and 61.1%, respectively.

Insulet’s Revenue

Year-on-year quarterly revenue growth grew by 25%, now sitting on 1.1B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Insulet’s stock is considered to be oversold (<=20).

Insulet’s Stock Yearly Top and Bottom Value

Insulet’s stock is valued at $211.84 at 17:33 EST, way below its 52-week high of $324.81 and way above its 52-week low of $181.00.

Insulet’s Moving Average

Insulet’s value is way under its 50-day moving average of $238.84 and way below its 200-day moving average of $265.85.

More news about Insulet.

7. GameStop (GME) – -9.42%

GameStop Corp. is a retailer of multi-channel consumer electronics and video games in America, Canada, Australia and Europe. It sells pre-owned and new video games platforms, accessories including controllers and virtual reality headsets as well as new and preowned software. The company also offers collectibles that include licensed merchandise that is primarily associated with the movie, TV, and videogame industries. It operates stores and ecommerce websites under the Micromania, GameStop and EB Games brands. The Zing Pop Culture brand also offers collectibles and Game Informer. This publication, which is both digital and print, features reviews, tips and information about the video gaming industry. The company had 5,509 shops in 14 countries as of February 1, 2020. GSC Holdings Corp. used to be the company’s name. GameStop Corp. was established in 1996 in Grapevine Texas.

NYSE ended the session with GameStop sliding 9.42% to $124.28 on Tuesday while NYSE rose 1.78% to $15,942.62.

Volume

Today’s last reported volume for GameStop is 4647860 which is 3.77% below its average volume of 4830020.

GameStop’s last close was $137.21, 60.19% under its 52-week high of $344.66.

News about GameStop today

  • Gamestop earnings preview: GME stock slides ahead of Wednesday results. According to today’s article on FXStreet, "This is a bad sign ahead of GameStop earnings slated to come out after the market closes on Wednesday. ", "GameStop’s new crypto wallet, called the GameStop Wallet, was released last week. "

The company’s growth estimates for the ongoing quarter and the next is a negative 222.2% and a negative 94.7%, respectively.

GameStop’s Revenue

Year-on-year quarterly revenue growth grew by 6.2%, now sitting on 6.01B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

GameStop’s stock is considered to be oversold (<=20).

GameStop’s Stock Yearly Top and Bottom Value

GameStop’s stock is valued at $124.28 at 17:33 EST, way under its 52-week high of $344.66 and way above its 52-week low of $77.58.

GameStop’s Moving Average

GameStop’s value is under its 50-day moving average of $129.19 and way below its 200-day moving average of $152.30.

More news about GameStop.

8. Snap (SNAP) – -9.24%

NYSE ended the session with Snap sliding 9.24% to $14.14 on Tuesday while NYSE jumped 1.78% to $15,942.62.

Volume

Today’s last reported volume for Snap is 89927000 which is 145.08% above its average volume of 36691800.

Snap’s last close was $15.58, 81.31% below its 52-week high of $83.34.

The company’s growth estimates for the ongoing quarter and the next is a negative 80% and a negative 41.2%, respectively.

Snap’s Revenue

Year-on-year quarterly revenue growth grew by 38.1%, now sitting on 4.41B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Snap’s stock is considered to be oversold (<=20).

Snap’s Stock Yearly Top and Bottom Value

Snap’s stock is valued at $14.14 at 17:33 EST, way below its 52-week low of $20.95.

Snap’s Moving Average

Snap’s value is way under its 50-day moving average of $30.98 and way under its 200-day moving average of $48.94.

More news about Snap.

9. Quidel (QDEL) – -8.69%

Quidel Corporation designs, produces, markets and sells diagnostic testing solutions worldwide for infectious diseases. The company offers the Sofia and Sofia2 fluorescent immunoassays systems, QuickVue, which is a lateral flow product, and InflammaDry, and AdenoPlus. These products are point-of care products that detect infectious and inflammatory conditions and eye conditions. Triage MeterPro is a handheld testing system that allows physicians to improve their health and detect certain drug abusers. Triage BNP tests can be used on Beckman Coulter laboratory analyzers. Triage TOX drug screens provide results for determining the presence and/or major metabolites of drugs in the urine. The company also offers cell-based products, such as tubes, shell vials and multi-well plates, that include traditional cell lines and specimen collection devices. Further, it provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. It also offers AmpliVue, a handheld molecular diagnostic platform that detects pathogens; Solana (an amplification-detection system); and Lyra molecular molecular real time polymerase chain reactions assays. Distributors and direct sales are the company’s channels of distribution. The products can be used in hospitals, clinics, reference labs, top universities, physician offices, pharmacy, wellness screening centers, pharmacies, urgent care clinics, medical laboratories and retail shops. Quidel Corporation was established in San Diego in 1979.

NASDAQ ended the session with Quidel falling 8.69% to $94.46 on Tuesday while NASDAQ fell 0.41% to $12,081.39.

Volume

Today’s last reported volume for Quidel is 1209210 which is 126.2% above its average volume of 534571.

Quidel’s last close was $103.45, 42.55% below its 52-week high of $180.06.

Quidel’s Sales

Quidel’s sales growth is 112.3% for the current quarter and a decline by 44.9% for the next. The company’s growth estimates for the ongoing quarter is 324% and a drop 83.4% for the next.

Quidel’s Revenue

Year-on-year quarterly revenue growth declined by 21.3%, now sitting on 1.7B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Quidel’s stock is considered to be oversold (<=20).

Quidel’s Stock Yearly Top and Bottom Value

Quidel’s stock is valued at $94.46 at 17:33 EST, way below its 52-week high of $180.06 and higher than its 52-week low of $88.05.

Quidel’s Moving Average

Quidel’s worth is way below its 50-day moving average of $106.05 and way below its 200-day moving average of $121.67.

More news about Quidel.

10. Pacific Biosciences of California (PACB) – -8.35%

Pacific Biosciences of California, Inc. develops, manufactures, and markets sequencing systems for complex genetic problems. The single-molecule real time (SMRT), sequencing technology allows for single-molecule detection of biological processes. The company offers a range of consumable products including SMRT cell technology and various reagent kit kits for specific workflows such as template preparation in order to transform DNA into SMRTbell double stranded DNA libraries formats. This includes molecular biology reagents such as ligase buffers exonucleases, buffers, and ligase. It also offers binding kits such as the modified DNA polymerase, which is used to bind SMRTbell library formats to the polymerase, in preparation to sequencing. Sequencing kits include reagents that are required to perform on-instrument real-time sequencing including the phospholinked molecular nucleotides. It serves commercial labs, genome centers, research institutes, genomics service providers, pharmaceutical companies, and agricultural businesses. The company markets its products via a direct sales force throughout North America and Europe as well as distribution partners across Asia, Europe and the Middle East. Asuragen and Pacific Biosciences have partnered to create assays that can be used for carrier screening, and many other purposes. They use SMRT sequencing technology. The original name of the company was Nanofluidics, Inc., but it changed its name in 2005 to Pacific Biosciences of California, Inc. Pacific Biosciences of California, Inc., was established in 2000. It is located in Menlo Park, California.

NASDAQ ended the session with Pacific Biosciences of California dropping 8.35% to $5.66 on Tuesday while NASDAQ fell 0.41% to $12,081.39.

Volume

Today’s last reported volume for Pacific Biosciences of California is 5840490 which is 10.01% below its average volume of 6490670.

Pacific Biosciences of California’s last close was $6.17, 83.03% under its 52-week high of $36.36.

Pacific Biosciences of California’s Sales

Pacific Biosciences of California’s sales growth is 17% for the current quarter and 30.3% for the next. The company’s growth estimates for the current quarter and the next is a negative 57.1% and a negative 500%, respectively.

Pacific Biosciences of California’s Revenue

Year-on-year quarterly revenue growth grew by 32.7%, now sitting on 130.51M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Pacific Biosciences of California’s stock is considered to be oversold (<=20).

Pacific Biosciences of California’s Stock Yearly Top and Bottom Value

Pacific Biosciences of California’s stock is valued at $5.66 at 17:33 EST, way below its 52-week high of $36.36 and way above its 52-week low of $4.51.

Pacific Biosciences of California’s Moving Average

Pacific Biosciences of California’s value is way under its 50-day moving average of $7.39 and way below its 200-day moving average of $17.48.

More news about Pacific Biosciences of California.

Stay up to date with our winners and losers daily report

LEAVE A REPLY

Please enter your comment!
Please enter your name here